A Study Evaluating the Use of 31P MRS to Assess Brain NAD+ Levels as Compared to Nicotinamide Riboside Supplementation in Healthy Current and Former Collegiate Athletes

Overview

About this study

The purpose of this study is to determine if nicotinamide riboside (750 mg/day for 12 weeks) can affect the levels of NAD+ in the brain as measured by 31P MRS.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

 

  • Current and former adult collegiate male and female athletes.
  • Aged 18 years and older.
  • Participants in football, rugby, soccer, hockey, lacrosse, and/or volleyball. 
    • Note:  “Former collegiate athletes” is defined as having competed in the applicable sports within the previous two years.
  • Body mass index (estimated based on height and weight) from 20 to 37.
  • Agree to maintain current level of physical activity throughout the study
  • Willing and able to provide written informed consent.
  • Willing and able to ingest the test substance.
  • Willing and able to comply with study instructions.
  • Not pregnant or breast feeding

Exclusion Criteria:

  • Presence of prolonged (more than 5 minutes) loss of consciousness.
  • Normal contraindications to MRI procedures, including but not limited to implanted medical (metal, magnetic, or electronic) devices or having metal objects or pacemakers.
  • History of epilepsy.
  • History of more than 3 concussions.
  • History of headache preceding concussions.
  • History of complex spine and/or skull traumas.
  • History of depression preceding concussions.
  • History of intracranial bleeding or strokes.
  • History of post-traumatic seizures.
  • History of developmental delay.
  • History of ADHD.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Brent Bauer, M.D.

Open for enrollment

Contact information:

Jennifer Soderlind

(507) 284-4799

Soderlind.Jennifer@mayo.edu

Minneapolis, Minn.

Mayo Clinic principal investigator

Brent Bauer, M.D.

Open for enrollment

Contact information:

Stephanie Lindeen R.N.

(507)284-4799

athletesstudy@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20201532

Mayo Clinic Footer